Gwendolyn Ho1,2, Ted Wun1, Lori Muffly3, Qian Li1, Ann Brunson1, Aaron S Rosenberg1, Brian A Jonas1, Theresa H M Keegan1. 1. Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, Department of Internal Medicine, University of California at Davis School of Medicine, Sacramento, California. 2. Department of Hematology Oncology, Kaiser Permanente North Valley, Sacramento, California. 3. Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California.
Abstract
BACKGROUND: To the authors' knowledge, few population-based studies to date have evaluated the association between location of care, complications with induction therapy, and early mortality in patients with acute myeloid leukemia (AML). METHODS: Using linked data from the California Cancer Registry and Patient Discharge Dataset (1999-2014), the authors identified adult (aged ≥18 years) patients with AML who received inpatient treatment within 30 days of diagnosis. A propensity score was created for treatment at a National Cancer Institute-designated cancer center (NCI-CC). Inverse probability-weighted, multivariable logistic regression models were used to determine associations between location of care, complications, and early mortality (death ≤60 days from diagnosis). RESULTS: Of the 7007 patients with AML, 1762 (25%) were treated at an NCI-CC. Patients with AML who were treated at NCI-CCs were more likely to be aged ≤65 years, live in higher socioeconomic status neighborhoods, have fewer comorbidities, and have public health insurance. Patients treated at NCI-CCs had higher rates of renal failure (23% vs 20%; P = .010) and lower rates of respiratory failure (11% vs 14%; P = .003) and cardiac arrest (1% vs 2%; P = .014). After adjustment for baseline characteristics, treatment at an NCI-CC was associated with lower early mortality (odds ratio, 0.46; 95% confidence interval, 0.38-0.57). The impact of complications on early mortality did not differ by location of care except for higher early mortality noted among patients with respiratory failure treated at non-NCI-CCs. CONCLUSIONS: The initial treatment of adult patients with AML at NCI-CCs is associated with a 53% reduction in the odds of early mortality compared with treatment at non-NCI-CCs. Lower early mortality may result from differences in hospital or provider experience and supportive care. Cancer 2018;124:1938-45.
BACKGROUND: To the authors' knowledge, few population-based studies to date have evaluated the association between location of care, complications with induction therapy, and early mortality in patients with acute myeloid leukemia (AML). METHODS: Using linked data from the California Cancer Registry and Patient Discharge Dataset (1999-2014), the authors identified adult (aged ≥18 years) patients with AML who received inpatient treatment within 30 days of diagnosis. A propensity score was created for treatment at a National Cancer Institute-designated cancer center (NCI-CC). Inverse probability-weighted, multivariable logistic regression models were used to determine associations between location of care, complications, and early mortality (death ≤60 days from diagnosis). RESULTS: Of the 7007 patients with AML, 1762 (25%) were treated at an NCI-CC. Patients with AML who were treated at NCI-CCs were more likely to be aged ≤65 years, live in higher socioeconomic status neighborhoods, have fewer comorbidities, and have public health insurance. Patients treated at NCI-CCs had higher rates of renal failure (23% vs 20%; P = .010) and lower rates of respiratory failure (11% vs 14%; P = .003) and cardiac arrest (1% vs 2%; P = .014). After adjustment for baseline characteristics, treatment at an NCI-CC was associated with lower early mortality (odds ratio, 0.46; 95% confidence interval, 0.38-0.57). The impact of complications on early mortality did not differ by location of care except for higher early mortality noted among patients with respiratory failure treated at non-NCI-CCs. CONCLUSIONS: The initial treatment of adult patients with AML at NCI-CCs is associated with a 53% reduction in the odds of early mortality compared with treatment at non-NCI-CCs. Lower early mortality may result from differences in hospital or provider experience and supportive care. Cancer 2018;124:1938-45.
Authors: Kevin G Billingsley; Arden M Morris; Jason A Dominitz; Barbara Matthews; Sharon Dobie; William Barlow; George E Wright; Laura-Mae Baldwin Journal: Arch Surg Date: 2007-01
Authors: Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez Journal: N Engl J Med Date: 2007-01-25 Impact factor: 91.245
Authors: Nancy J O Birkmeyer; Philip P Goodney; Therese A Stukel; Bruce E Hillner; John D Birkmeyer Journal: Cancer Date: 2005-02-01 Impact factor: 6.860
Authors: David A Etzioni; Tonia M Young-Fadok; Robert R Cima; Nabil Wasif; Robert D Madoff; James M Naessens; Elizabeth B Habermann Journal: Cancer Date: 2014-05-06 Impact factor: 6.860
Authors: Karl Y Bilimoria; Mark S Talamonti; Jeffrey D Wayne; James S Tomlinson; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem Journal: Arch Surg Date: 2008-07
Authors: Jane C Weeks; Hajime Uno; Nathan Taback; Gladys Ting; Angel Cronin; Thomas A D'Amico; Jonathan W Friedberg; Deborah Schrag Journal: Ann Intern Med Date: 2014-07-01 Impact factor: 25.391
Authors: Amer M Zeidan; Nikolai A Podoltsev; Xiaoyi Wang; Chi Zhang; Jan Philipp Bewersdorf; Rory M Shallis; Scott F Huntington; Natalia Neparidze; Smith Giri; Steven D Gore; Amy J Davidoff; Xiaomei Ma; Rong Wang Journal: Blood Adv Date: 2020-04-28
Authors: Hagop M Kantarjian; Nitin Jain; Guillermo Garcia-Manero; Mary Alma Welch; Farhad Ravandi; William G Wierda; Elias J Jabbour Journal: Cancer Date: 2021-10-06 Impact factor: 6.860
Authors: Hagop Kantarjian; Nicholas J Short; Courtney DiNardo; Eytan M Stein; Naval Daver; Alexander E Perl; Eunice S Wang; Andrew Wei; Martin Tallman Journal: Lancet Haematol Date: 2021-10-20 Impact factor: 18.959
Authors: Naama Keren-Froim; Gabriel Heering; Gal Sharvit; Maya Zlotnik; Arnon Nagler; Avichai Shimoni; Abraham Avigdor; Jonathan Canaani Journal: Ann Hematol Date: 2022-01-06 Impact factor: 3.673